GlassScriptPhysician profile
Julio A Meza
NPI 1013678036
$5,204.63
in general payments reported to CMS, 2019-2025
39 companies · $2,718 in 2025
The $2,718 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $431 · 2024: $2,056 · 2025: $2,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,195 · Education: $9.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,194.89 |
| Education | $9.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $907.65 | 2023-2025 | Briviact, Zilbrysq, Nayzilam |
| Neurocrine Biosciences, INC. | $445.13 | 2023-2025 | Ingrezza |
| Pfizer INC. | $373.00 | 2023-2025 | |
| Celgene Corporation | $368.32 | 2023-2024 | Zeposia |
| Biogen, INC. | $324.19 | 2024-2025 | Tysabri, Vumerity, Qalsody |
| Abbvie INC. | $311.09 | 2024-2025 | |
| Argenx US, INC. | $305.79 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $282.43 | 2023-2025 | Vyepti, Rexulti |
| Catalyst Pharmaceuticals, INC. | $191.24 | 2024-2025 | |
| Neurelis, INC. | $187.52 | 2024-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $157.21 | 2023-2025 | Rexulti, Nuedexta |
| Genentech USA, INC. | $121.07 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $119.59 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Csl Behring | $100.99 | 2023-2024 | Hizentra |
| Ani Pharmaceuticals, INC. | $96.51 | 2024-2025 | Purified Cortrophin Gel |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $90.65 | 2025 | Symbravo |
| Mdd US Operations, LLC | $81.44 | 2025 | Gocovri, Qelbree |
| Jazz Pharmaceuticals INC. | $79.17 | 2025 | |
| Vanda Pharmaceuticals INC. | $69.61 | 2025 | Ponvory |
| Scilex Pharmaceuticals INC. | $63.71 | 2025 | |
| Alexion Pharmaceuticals, INC. | $55.69 | 2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $52.15 | 2023-2024 | Rytary |
| Sk Life Science, INC. | $51.09 | 2024-2025 | |
| Amgen INC. | $45.86 | 2024-2025 | Uplizna |
| Lilly USA, LLC | $40.86 | 2023-2024 | Emgality, Amyvid |
| Cala Health, INC. | $33.42 | 2025 | Cala Kiq |
| Avadel Cns Pharmaceuticals, LLC | $32.04 | 2025 | Lumryz |
| Microtransponder, INC. | $23.74 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.33 | 2025 | |
| Averitas Pharma INC. | $21.79 | 2023 | Qutenza |
| Tersera Therapeutics LLC | $19.27 | 2025 | Quzyttir |
| Janssen Biotech, INC. | $18.51 | 2025 | |
| Octapharma USA, INC. | $18.05 | 2023 | Panzyga |
| Eisai INC. | $17.64 | 2025 | |
| Kyowa Kirin, INC. | $17.46 | 2024 | Nourianz |
| Livanova USA, INC. | $16.43 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $14.36 | 2025 | |
| Grifols USA, LLC | $14.08 | 2025 | Gamunex-C |
| Abbott Laboratories | $13.55 | 2025 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Meza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.